The financials
Bio-Rad Laboratories, Inc. by the numbers
Bio-Rad Laboratories, Inc. (BIO) reported revenue of $592M in Q1 2026 (quarter ended March 31, 2026), up 1.1% from the same quarter a year earlier. That came with a gross margin of 52% and net loss of $527M. For the full year FY2025, revenue was $2.58B (+0.7% year on year) and net income $760M. Its largest region in 2026-Q1 was US at $230M, 39% of the disclosed total, just ahead of Europe at 35%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $592M | $585M | +1.1% |
| Gross profit | $309M | $306M | +1.1% |
| Operating income | $34M | $24M | +44% |
| Net income | −$527M | $64M | to a loss |
| Diluted EPS | −$19.55 | $2.29 | to a loss |
| Geographic | Revenue | Share |
|---|---|---|
| US | $230M | 39% |
| Europe | $207M | 35% |
| Asia Pacific | $110M | 19% |
| Americas | $45M | 7.6% |
Business Segments
Revenue split by geographic segment, from SEC XBRL filings.
Latest period: Q1 2026Total $592.1M (-9.3%)
Americas grew +13% year on yearUS -4.9% year on year
Segment Latestquarter on quarteryear on year
- US$229.8M$229.8MQoQ -15%year on year -4.9%-15%-4.9%
- Europe$206.8M$206.8MQoQ -6.9%year on year +3.5%-6.9%+3.5%
- Asia Pacific$110.4M$110.4MQoQ -8.8%year on year +6.1%-8.8%+6.1%
- Americas$45.1M$45.1MQoQ +13%year on year +13%+13%+13%
Medical Devices
Ranks #27 of 35 by Smart Score